{"name":"AIO-Studien-gGmbH","slug":"aio-studien-ggmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Epirubicin, Cisplatin, Capecitabine, Panitumumab","genericName":"Epirubicin, Cisplatin, Capecitabine, Panitumumab","slug":"epirubicin-cisplatin-capecitabine-panitumumab","indication":"Other","status":"phase_2"},{"name":"Fluorouracil, leucovorin, oxaliplatin, docetaxel","genericName":"Fluorouracil, leucovorin, oxaliplatin, docetaxel","slug":"fluorouracil-leucovorin-oxaliplatin-docetaxel","indication":"Other","status":"phase_2"},{"name":"S-1 de-escalation","genericName":"S-1 de-escalation","slug":"s-1-de-escalation","indication":"Other","status":"phase_2"},{"name":"Vinorebine, Everolimus","genericName":"Vinorebine, Everolimus","slug":"vinorebine-everolimus","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"FOLFIFINOX","genericName":"FOLFIFINOX","slug":"folfifinox","indication":"Metastatic pancreatic cancer","status":"phase_2"}]}],"pipeline":[{"name":"Epirubicin, Cisplatin, Capecitabine, Panitumumab","genericName":"Epirubicin, Cisplatin, Capecitabine, Panitumumab","slug":"epirubicin-cisplatin-capecitabine-panitumumab","phase":"phase_2","mechanism":"Combines DNA-damaging chemotherapy agents with EGFR inhibition to attack cancer cells through multiple pathways.","indications":[],"catalyst":""},{"name":"Fluorouracil, leucovorin, oxaliplatin, docetaxel","genericName":"Fluorouracil, leucovorin, oxaliplatin, docetaxel","slug":"fluorouracil-leucovorin-oxaliplatin-docetaxel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FOLFIFINOX","genericName":"FOLFIFINOX","slug":"folfifinox","phase":"phase_2","mechanism":"FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.","indications":["Metastatic pancreatic cancer"],"catalyst":""},{"name":"S-1 de-escalation","genericName":"S-1 de-escalation","slug":"s-1-de-escalation","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vinorebine, Everolimus","genericName":"Vinorebine, Everolimus","slug":"vinorebine-everolimus","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":5},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}